FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379981562> ?p ?o ?g. }

• W4379981562 endingPage "478" @default.
• W4379981562 startingPage "477" @default.
• W4379981562 abstract "Introduction: Deciphering molecular determinants of response to targeted treatments and early detection of refractoriness in patients with relapsed and refractory (R/R) mantle cell lymphoma (MCL) could individualize treatment, improve outcomes and limit unnecessary toxicities. Circulating tumor DNA (ctDNA) allows non-invasive profiling and measurement of treatment responses. Yet, increased sensitivity for detection and distinction from confounding biological signals are warranted. Enhanced ctDNA detection can be achieved using duplex sequencing or tracing of phased variants. Poor recovery of complementary strands and low number of phased variants limit the feasibility of these approaches separately in MCL. Methods: Thus, we developed and optimized a hybrid ctDNA sequencing platform, which combines strand- and phasing-aware error correction methods for improved specificity and sensitivity of non-invasive B-cell lymphoma profiling, quantification and detection (Figure 1A). We applied this platform to profile ctDNA in serial plasma samples from 59 patients with R/R MCL treated with lenalidomide, venetoclax and rituximab in the Nordic phase II trial (NLG-MCL7; VALERIA). We compared the results with outcomes and real-time quantified PCR (RQ-PCR, ‘Euro-Minimal Residual Disease (MRD’)) data from bone marrow (BM) and peripheral blood (PB) samples that guided therapy in the trial (Figure 1B). Results: Joint analysis of targeted sequences from pretreatment tumor, PB, BM, and plasma samples revealed MCL genotypes for ctDNA tracing even in the patients who failed primer designs for Euro-MRD (Figure 1C). Comparison between genotyping of samples from different compartments from individual patients mitigated confounding clonal hematopoiesis background and revealed spatially-confined MCL mutations. TP53 mutated MCL conferred resistance to therapy, whereas SMARCA4 mutations translated into durable molecular remission (Figure 1D-E). Elevated pretreatment ctDNA concentration was associated with multiple clinical risk factors, leukemic disease, and poor outcome (Figure 1F). After six months of therapy, ctDNA levels dropped in all studied patients. The responses in the ctDNA were highly concordant with concomitant Euro-MRD and extended to patients not evaluable by RQ-PCR. Notably, contrasting ctDNA clearance, the analysis of the post-therapy cell-free DNA revealed positive selection of clonal hematopoiesis drivers following therapy exposure, such as TP53 mutations in 77% of the patients. The research was funded by: Academy of Finland, iCAN Flagship, University of Helsinki, Helsinki University Hospital, Finnish Cancer Organisation, Sigrid Juselius Foundation and Abbvie. Keywords: diagnostic and prognostic biomarkers, liquid biopsy, molecular targeted therapies No conflicts of interests pertinent to the abstract." @default.
• W4379981562 created "2023-06-10" @default.
• W4379981562 creator A5000211575 @default.
• W4379981562 creator A5010381524 @default.
• W4379981562 creator A5013263576 @default.
• W4379981562 creator A5028743667 @default.
• W4379981562 creator A5031476005 @default.
• W4379981562 creator A5036325940 @default.
• W4379981562 creator A5051888634 @default.
• W4379981562 creator A5057884204 @default.
• W4379981562 creator A5059017152 @default.
• W4379981562 creator A5063458390 @default.
• W4379981562 creator A5067329171 @default.
• W4379981562 date "2023-06-01" @default.
• W4379981562 modified "2023-09-24" @default.
• W4379981562 title "Enhanced ctDNA Profiling Reveals Molecular Determinants of Response and Resistance in Relapsed and Refractory Mantle Cell Lymphoma (NLG‐MCL7‐VALERIA)" @default.
• W4379981562 doi "https://doi.org/10.1002/hon.3164_351" @default.
• W4379981562 hasPublicationYear "2023" @default.
• W4379981562 type Work @default.
• W4379981562 citedByCount "0" @default.
• W4379981562 crossrefType "journal-article" @default.
• W4379981562 hasAuthorship W4379981562A5000211575 @default.
• W4379981562 hasAuthorship W4379981562A5010381524 @default.
• W4379981562 hasAuthorship W4379981562A5013263576 @default.
• W4379981562 hasAuthorship W4379981562A5028743667 @default.
• W4379981562 hasAuthorship W4379981562A5031476005 @default.
• W4379981562 hasAuthorship W4379981562A5036325940 @default.
• W4379981562 hasAuthorship W4379981562A5051888634 @default.
• W4379981562 hasAuthorship W4379981562A5057884204 @default.
• W4379981562 hasAuthorship W4379981562A5059017152 @default.
• W4379981562 hasAuthorship W4379981562A5063458390 @default.
• W4379981562 hasAuthorship W4379981562A5067329171 @default.
• W4379981562 hasBestOaLocation W43799815621 @default.
• W4379981562 hasConcept C104317684 @default.
• W4379981562 hasConcept C121608353 @default.
• W4379981562 hasConcept C126322002 @default.
• W4379981562 hasConcept C135763542 @default.
• W4379981562 hasConcept C143998085 @default.
• W4379981562 hasConcept C2776063141 @default.
• W4379981562 hasConcept C2776364478 @default.
• W4379981562 hasConcept C2777525834 @default.
• W4379981562 hasConcept C2779338263 @default.
• W4379981562 hasConcept C2779823535 @default.
• W4379981562 hasConcept C2780007613 @default.
• W4379981562 hasConcept C2781335228 @default.
• W4379981562 hasConcept C31467283 @default.
• W4379981562 hasConcept C502942594 @default.
• W4379981562 hasConcept C54355233 @default.
• W4379981562 hasConcept C71924100 @default.
• W4379981562 hasConcept C86803240 @default.
• W4379981562 hasConceptScore W4379981562C104317684 @default.
• W4379981562 hasConceptScore W4379981562C121608353 @default.
• W4379981562 hasConceptScore W4379981562C126322002 @default.
• W4379981562 hasConceptScore W4379981562C135763542 @default.
• W4379981562 hasConceptScore W4379981562C143998085 @default.
• W4379981562 hasConceptScore W4379981562C2776063141 @default.
• W4379981562 hasConceptScore W4379981562C2776364478 @default.
• W4379981562 hasConceptScore W4379981562C2777525834 @default.
• W4379981562 hasConceptScore W4379981562C2779338263 @default.
• W4379981562 hasConceptScore W4379981562C2779823535 @default.
• W4379981562 hasConceptScore W4379981562C2780007613 @default.
• W4379981562 hasConceptScore W4379981562C2781335228 @default.
• W4379981562 hasConceptScore W4379981562C31467283 @default.
• W4379981562 hasConceptScore W4379981562C502942594 @default.
• W4379981562 hasConceptScore W4379981562C54355233 @default.
• W4379981562 hasConceptScore W4379981562C71924100 @default.
• W4379981562 hasConceptScore W4379981562C86803240 @default.
• W4379981562 hasIssue "S2" @default.
• W4379981562 hasLocation W43799815621 @default.
• W4379981562 hasOpenAccess W4379981562 @default.
• W4379981562 hasPrimaryLocation W43799815621 @default.
• W4379981562 hasRelatedWork W2037863335 @default.
• W4379981562 hasRelatedWork W2059624852 @default.
• W4379981562 hasRelatedWork W2231840386 @default.
• W4379981562 hasRelatedWork W2281379608 @default.
• W4379981562 hasRelatedWork W2331171288 @default.
• W4379981562 hasRelatedWork W3112654935 @default.
• W4379981562 hasRelatedWork W4200029042 @default.
• W4379981562 hasRelatedWork W4238372476 @default.
• W4379981562 hasRelatedWork W72650883 @default.
• W4379981562 hasRelatedWork W74504067 @default.
• W4379981562 hasVolume "41" @default.
• W4379981562 isParatext "false" @default.
• W4379981562 isRetracted "false" @default.
• W4379981562 workType "article" @default.